Literature DB >> 23127919

The effects of vaccination on serum hormone concentrations and conception rates in synchronized naive beef heifers.

George A Perry1, Alicia D Zimmerman, Russell F Daly, Robin E Buterbaugh, Jim Rhoades, Doug Scholz, Aaron Harmon, Christopher C L Chase.   

Abstract

Crossbred beef heifers (N = 59) were vaccinated at the time of synchronization/breeding with either a commercially available bovine herpesvirus type 1 modified live virus (MLV) (one dose) or inactivated virus vaccine (one or two doses). The estrus cycle was synchronized at vaccination and heifers were artificially inseminated 8 days (one dose) or 36 days (two dose) after initial vaccination. Pregnancy rates were greater for control heifers (90%; P = 0.02) and heifers given the inactivated virus vaccine (one dose: 86%; P = 0.08; or two: 90%; P < 0.01) than those given the MLV vaccine (48%). No control heifers experienced an abnormal estrous cycle, whereas only two (two dose; 2/21) and one (one dose; 1/7) heifers in the inactive virus groups had abnormal estrous cycles and were similar to control (P > 0.10). Heifers given the MLV vaccine had a greater (P = 0.02) percentage of abnormal estrous cycles (38%; 8/21) compared with the control and inactivated groups. Of the heifers with an abnormal estrous cycle, 100% of heifers given the inactivated vaccine (one or two dose) conceived at their return estrus, whereas only 38% of heifers given the MLV vaccine conceived at their return estrus (P > 0.10). During the synchronization period, concentrations of estrogen were greater (P < 0.01) in the control and the two-dose inactivated group compared with the MLV group. After AI, progesterone concentrations were greater (P < 0.01) in control heifers compared with the inactivated and MLV groups, but were similar (P ≥ 0.18) between the inactivated and MLV groups. Therefore, naïve heifers vaccinated with the inactivated vaccine were less likely to have an abnormal estrous cycle and had significantly higher pregnancy rates compared with heifers vaccinated with the MLV vaccine. In summary, vaccination of naïve heifers with an MLV vaccine at the start of a fixed-time AI protocol had a negative effect on pregnancy success.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127919     DOI: 10.1016/j.theriogenology.2012.10.005

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  5 in total

1.  Progesterone increases the incidence of bovine herpesvirus 1 reactivation from latency and stimulates productive infection.

Authors:  Fouad S El-Mayet; Laximan Sawant; Nishani Wijesekera; Clinton Jones
Journal:  Virus Res       Date:  2019-11-04       Impact factor: 3.303

2.  Progesterone Sporadically Induces Reactivation from Latency in Female Calves but Proficiently Stimulates Bovine Herpesvirus 1 Productive Infection.

Authors:  Fouad S El-Mayet; Gabriela Toomer; Jeffery B Ostler; Kelly S Harrison; Vanessa Claire Santos; Nishani Wijesekera; Erin Stayton; Jerry Ritchey; Clinton Jones
Journal:  J Virol       Date:  2022-01-12       Impact factor: 6.549

3.  Synergistic Activation of Bovine Herpesvirus 1 Productive Infection and Viral Regulatory Promoters by the Progesterone Receptor and Krüppel-Like Transcription Factor 15.

Authors:  Fouad S El-Mayet; Ayman S El-Habbaa; Jean D'Offay; Clinton Jones
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

Review 4.  Bovine Herpesvirus 1 Counteracts Immune Responses and Immune-Surveillance to Enhance Pathogenesis and Virus Transmission.

Authors:  Clinton Jones
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

5.  Bovine viral diarrhea virus: An updated American College of Veterinary Internal Medicine consensus statement with focus on virus biology, hosts, immunosuppression, and vaccination.

Authors:  Paul H Walz; Manuel F Chamorro; Shollie M Falkenberg; Thomas Passler; Frank van der Meer; Amelia R Woolums
Journal:  J Vet Intern Med       Date:  2020-07-07       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.